{
    "medicine_id": "4eb4956580ce3125d7f761629bdecec04cc459f0",
    "platform_id": "DB05776",
    "metadata": {
        "name": "Kadcyla 160 mg Powder for solution",
        "composition": "160 mg IC41",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in hepatitis viral C",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "IC41 is able of inducing a significant proliferative response in chronic HCV patients IC41 can induce interferon gamma secreting T cells in chronic HCV patients Interferon gamma secretion is a hallmark of type I T cell responses Such responses are seen during the acute phase of infection in the subset of HCV patients who eliminate the virus and do not proceed to chronic infection Induction of type I T cell responses as achieved by IC41 is a primary goal of therapeutic vaccination against HCV",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}